| Citation: |
LEI Qingsong, LI Lin. Construction of Prognostic Model for Cuprotosis in Hepatocellular Carcinoma Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 276-282. DOI: 10.3971/j.issn.1000-8578.2023.22.0875
|
To construct a prognostic model for cuprotosis-related genes (CRGs) in patients with hepatocellular carcinoma (HCC).
Differential expression of CRGs in HCC was analyzed on the basis of datasets from the TCGA database. The potential mechanisms of CRGs and their related genes in HCC were explored through GO and KEGG enrichment analyses. The prognostic value of the CRGs was evaluated through Kaplan-Meier survival analysis, and the relationship between CRG expression and immune cell infiltration was investigated. CRGs significantly correlated with prognosis in patients with HCC were identified. A prognostic model was established through univariate, Lasso regression, and multivariate Cox regression analyses. The patients were divided into two groups by risk score. ROC curve was used in evaluating the prognostic model. The relationship of risk score or clinical factors with prognosis was analyzed through univariate and multivariate Cox regression analyses.
A total of 11 differentially expressed CRGs in HCC were obtained. The main enriched GO item of CRGs and their related genes was oxidoreductase activity, acting on the aldehyde or oxo group of donors, and the main enriched KEGG pathway was carbon metabolism. The expression of CRGs was significantly correlated with pDC, T helper cells and other immune cells (P < 0.05). Three CRGs (CDKN2A, DLAT, and LIPT1) were screened and a prognostic model was constructed. There was significant difference in overall survival between the high- and low-risk groups (P < 0.001). The risk score is an independent risk factor for poor prognosis (P < 0.001).
The prognostic model for CRGs in patients with HCC is constructed using TCGA database data. This model may be used in evaluating patient prognosis.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
| [2] |
Moriguchi M, Aramaki T, Nishiofuku H, et al. Sorafenib versus hepatic arterial infusion chemotherapy as initial treatment for hepatocellular carcinoma with advanced portal vein tumor thrombosis[J]. Liver Cancer, 2017, 6(4): 275-286. doi: 10.1159/000473887
|
| [3] |
Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604. doi: 10.1038/s41575-019-0186-y
|
| [4] |
Yu M, Ren L, Zheng M, et al. Delayed Diagnosis of Wilson's disease report from 179 newly diagnosed cases in China[J]. Front Neurol, 2022, 13: 884840. doi: 10.3389/fneur.2022.884840
|
| [5] |
Guo Y, Xia W, Peng X, et al. Almost misdiagnosed Menkes disease: A case report[J]. Heliyon, 2022, 8(4): e09268. doi: 10.1016/j.heliyon.2022.e09268
|
| [6] |
李圣豪, 石新丽. 原发性肝癌中PD-L1表达的调控机制[J]. 肿瘤防治研究, 2021, 48(11): 1052-1058. doi: 10.3971/j.issn.1000-8578.2021.21.0397
Li SH, Shi XL. Regulatory mechanism of PD-L1 expression in primary liver cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2021, 48(11): 1052-1058. doi: 10.3971/j.issn.1000-8578.2021.21.0397
|
| [7] |
黄乾荣, 张玲. 原发性肝癌治疗研究新进展[J]. 实用医学杂志, 2016, 32(14): 2275-2278. doi: 10.3969/j.issn.1006-5725.2016.14.008
Huang QR, Zhang L. Advances in the treatment of primary liver cancer[J]. Shi Yong Yi Xue Za Zhi, 2016, 32(14): 2275-2278. doi: 10.3969/j.issn.1006-5725.2016.14.008
|
| [8] |
Li Y. Copper homeostasis: Emerging target for cancer treatment[J]. IUBMB Life, 2020, 72(9): 1900-1908. doi: 10.1002/iub.2341
|
| [9] |
Shanbhag VC, Gudekar N, Jasmer K, et al. Copper metabolism as a unique vulnerability in cancer[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868(2): 118893. doi: 10.1016/j.bbamcr.2020.118893
|
| [10] |
Ge EJ, Bush AI, Casini A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia[J]. Nat Rev Cancer, 2022, 22(2): 102-113. doi: 10.1038/s41568-021-00417-2
|
| [11] |
Tawari PE, Wang Z, Najlah M, et al. The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells[J]. Toxicol Res (Camb), 2015, 4(6): 1439-1442. doi: 10.1039/c5tx00210a
|
| [12] |
Li Y, Wang LH, Zhang HT, et al. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways[J]. J Cell Mol Med, 2018, 22(1): 439-451. doi: 10.1111/jcmm.13334
|
| [13] |
Nirmala JG, Lopus M. Cell death mechanisms in eukaryotes[J]. Cell Biol Toxicol, 2020, 36(2): 145-164. doi: 10.1007/s10565-019-09496-2
|
| [14] |
Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261. doi: 10.1126/science.abf0529
|
| [15] |
Gao W, Huang Z, Duan J, et al. Elesclomol induces copperdependent ferroptosis in colorectal cancer cells via degradation of ATP7A[J]. Mol Oncol, 2021, 15(12): 3527-3544. doi: 10.1002/1878-0261.13079
|
| [16] |
Skrott Z, Mistrik M, Andersen KK, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4[J]. Nature, 2017, 552(7684): 194-199. doi: 10.1038/nature25016
|
| [17] |
Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress[J]. Nat Chem Biol, 2019, 15(7): 681-689. doi: 10.1038/s41589-019-0291-9
|
| [18] |
Soma S, Latimer AJ, Chun H, et al. Elesclomol restores mitochondrial function in genetic models of copper deficiency[J]. Proc Natl Acad Sci U S A, 2018, 115(32): 8161-8166. doi: 10.1073/pnas.1806296115
|
| [19] |
孙明明, 乔亚亚, 李垒垒, 等. 二氢硫辛酰转乙酰基酶通过乙酰化磷酸葡糖酸脱氢酶促进核酸合成[J]. 中国生物化学与分子生物学报, 2021, 37(3): 339-346. https://www.cnki.com.cn/Article/CJFDTOTAL-SWHZ202103009.htm
Sun MM, Qiao YY, Li LL, et al. Dihydrolipoamide acetyltransferase promotes nucleic acid synthesis by controlling phosphogluconate dehydrogenase acetylation[J]. Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao, 2021, 37(3): 339-346. https://www.cnki.com.cn/Article/CJFDTOTAL-SWHZ202103009.htm
|
| [20] |
Sun J, Li J, Guo Z, et al. Overexpression of Pyruvate Dehydrogenase E1α Subunit Inhibits Warburg Effect and Induces Cell Apoptosis Through Mitochondria-Mediated Pathway in Hepatocellular Carcinoma[J]. Oncol Res, 2019, 27(4): 407-414. doi: 10.3727/096504018X15180451872087
|
| [21] |
曹俊, 柏斗胜, 金圣杰, 等. 谷氨酰胺酶1介导主穹隆蛋白表达调控肝内胆管癌细胞对5-氟尿嘧啶化疗敏感性的研究[J]. 中华普通外科杂志, 2019, 28(3): 248-252. https://cdmd.cnki.com.cn/Article/CDMD-11117-1020051370.htm
Cao J, Bai DS, Jin SJ, et al. Glutamine 1 regulates the chemosensitivity of intrahepatic cholangiocarcinoma cells to 5-FU by targeting major vault protein[J]. Zhonghua Pu Tong Wai Ke Za Zhi, 2019, 28(3): 248-252. https://cdmd.cnki.com.cn/Article/CDMD-11117-1020051370.htm
|
| [22] |
Lv H, Liu X, Zeng X, et al. Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma[J]. Front Pharmacol, 2022, 13: 930041. doi: 10.3389/fphar.2022.930041
|
| [23] |
Arnoff TE, El-Deiry WS. MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and immunotherapy[J]. Am J Cancer Res, 2022, 12(5): 2102-2117.
|
| [24] |
Lee DY, Kim EH. Therapeutic Effects of Amino Acids in Liver Diseases: Current Studies and Future Perspectives[J]. J Cancer Prev, 2019, 24(2): 72-78. doi: 10.15430/JCP.2019.24.2.72
|
| [25] |
An J, Ha EM. Extracellular vesicles derived from Lactobacillus plantarum restore chemosensitivity through the PDK2-mediated glucose metabolic pathway in 5-FU-resistant colorectal cancer cells[J]. J Microbiol, 2022, 60(7): 735-745. doi: 10.1007/s12275-022-2201-1
|
| [26] |
尤晓昕, 张丹, 李尔广. 氨基酸代谢重编程在肿瘤发生发展及免疫治疗中的作用[J]. 中国细胞生物学学报, 2021, 43(9): 1846-1852. https://www.cnki.com.cn/Article/CJFDTOTAL-XBZZ202109016.htm
You XX, Zhang D, Li EG. Amino acid metabolic reprogramming in tumorigenesis and development and its role in immunotherapy[J]. Zhongguo Xi Bao Sheng Wu Xue Xue Bao, 2021, 43(9): 1846-1852. https://www.cnki.com.cn/Article/CJFDTOTAL-XBZZ202109016.htm
|
| [27] |
Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis[J]. Annu Rev Pathol, 2013, 8: 303-330. doi: 10.1146/annurev-pathol-020712-164014
|
| [28] |
Edwards DN, Ngwa VM, Raybuck AL, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer[J]. J Clin Invest, 2021, 131(4): e140100. doi: 10.1172/JCI140100
|
| [29] |
Wang J, Peng C, Dai W, et al. Exploring Tumor Immune Microenvironment and Its Associations With Molecular Characteristics in Melanoma[J]. Front Oncol, 2022, 12: 821578. doi: 10.3389/fonc.2022.821578
|
| [30] |
Liu H, Jia S, Guo K, et al. INK4 cyclin-dependent kinase inhibitors as potential prognostic biomarkers and therapeutic targets in hepatocellular carcinoma[J]. Biosci Rep, 2022, 42(7): BSR20221082. doi: 10.1042/BSR20221082
|
| [31] |
Luo JP, Wang J, Huang JH. CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma[J]. Biosci Rep, 2021, 41(10): BSR20211103. doi: 10.1042/BSR20211103
|
| [32] |
Zhang C, Feng S, Tu Z, et al. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome[J]. Cancer Med, 2021, 10(18): 6227-6238. doi: 10.1002/cam4.4162
|
| [33] |
Boerner T, Drill E, Pak LM, et al. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma[J]. Hepatology, 2021, 74(3): 1429-1444. doi: 10.1002/hep.31829
|
| [34] |
王婷, 李春晓, 南鹏, 等. 基于多数据库分析代谢相关基因DLAT在结直肠癌中的表达及其临床意义[J]. 解放军医学杂志, 2019, 44(4): 311-317. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY201904008.htm
Wang T, Li CX, Nan P, et al. Analysis of metabolic associated gene DLAT expression in colorectal cancer based on multi-database and its clinical significance[J]. Jiefangjun Yi Xue Za Zhi, 2019, 44(4): 311-317. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY201904008.htm
|
| [35] |
Goh WQ, Ow GS, Kuznetsov VA, et al. DLAT subunit of the pyruvate dehydrogenase complex is upregulated in gastric cancerimplications in cancer therapy[J]. Am J Transl Res, 2015, 7(6): 1140-1151.
|
Figures(5) / Tables(2)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: